Business Wire

Citi Global Wealth Investments Issues Mid-Year Wealth Outlook 2023 - Opportunities on the Horizon: Investing Through a Slowing Economy

Share

Citi Global Wealth Investments today released its Mid-Year Wealth Outlook 2023 report - Opportunities on the Horizon: Investing Through a Slowing Economy. This biannual report sets out Citi Global Wealth’s outlook on how investors should approach developments in the global economy, markets and geopolitics.

Though 2023 has been full of extraordinary events, Citi Global Wealth sees the remainder of the year as an opportunity. We are in a “rolling recession” where parts of the US economy are growing even as others contract. As inflation slowly eases following a period of rapid Fed rate hikes, the group believes that keeping portfolios invested is imperative. While the current asset allocation strategy remains defensive, Citi Global Wealth see numerous opportunities to adjust their portfolios over time, as the Fed shifts from interest rate hikes to cuts.

We believe that current markets will lead into a meaningful potential recovery in 2024.

“Though the broader bear market is not yet over, we are seeing significant valuation improvements in certain sectors that provide our clients with the potential to invest in higher income-generating assets and long-term growth opportunities,” said David Bailin, Chief Investment Officer at Citi Global Wealth. “Our wealth outlook for the remainder of 2023 and heading into 2024 suggests that clients may benefit most from a return to what we call ‘core investing’ – full invested portfolios that move from defense to offense, from more bonds to more equities, from US-focused to global. We favor investing in select non-U.S. equities, identifying value within U.S. markets, broadening tech and growth equity exposures and emphasizing alternative investing and private credit for suitable investors with a longer time horizon.”

Bonds are Back Again: Sustaining Income as Rates Peak

Citi Global Wealth believes that it is time for action in the fixed income space. Investors holding short term investments can seek to extend their income by extending duration. There are also many potential opportunities to diversify bond portfolios, add to duration, diversity risk and earn potentially higher yields. And private credit can add significant yield as banks retrench. Best of all, bonds will now provide the diversification benefits they lost temporarily in 2022.

Diversity Currency Exposure

The U.S. dollar (USD) rose for a decade through 2022 and saw a boost from excessive Fed tightening and energy shocks related to the war in Ukraine. The rise in the USD sharply inflated US home-biased portfolios verses portfolios holding other currencies. US equities rose to 63% of the global market cap in 2022.

As the ECB and other central banks hold rates steady in 2024 while the Fed eases, there can be opportunities for clients to diversify into non-USD assets, seeking to improve investor returns in the decade ahead.

“The strong U.S. dollar means we can buy non-U.S. assets at deeply deflated prices,” said Steven Wieting, Chief Economist and Chief Investment Strategist at Citi Global Wealth. “While we expect periodic US dollar rallies, we ultimately will see a weakening dollar, making currency exposure more critical. In addition to currency exposure, we are favoring quality, such as long-duration bonds to offset a potential credit spread widening and defensive equities with an emphasis on dividend growers and companies with strong balance sheets. As we prepare portfolios for the Fed pivot at the end of 2023, we look for industry-leading growth shares to bottom before cyclicals.”

Unstoppable Trends

Citi Global Wealth’s “Unstoppable Trends” are transformative global forces that can inform change in client portfolios.

The Mid-Year Wealth Outlook 2023 defines the following trends:

  • Digitization - Generative AI is the beginning of (another) technological revolution: the rapid adoption of AI opens the door to significant investment opportunities in the ecosystem
  • Energy Security: Unusual opportunities in an atypical energy cycle: World events and the rise of renewable energy are reshaping the energy landscape
  • G2: Putting national security interests ahead of economic cooperation: Intensifying U.S.-China tension creates challenges and opportunities for investors
  • Invest in Longevity: Healthcare demand continues to grow faster than the world economy, proving non-cyclical growth for portfolios

See Citi Global Wealth’s full Mid-Year Wealth Outlook report for full details.

About Citi Global Wealth

Citi Global Wealth is an integrated wealth management platform that delivers a total wealth solution to clients across the wealth continuum, with integrated advice and execution across both their assets and liabilities. Citi Global Wealth serves ultra-high-net-worth individuals and family offices through Citi Private Bank, operates in the affluent and high-net worth segments through Citigold® and Citigold Private Client and captures wealth management in the workplace through Global Wealth at Work. Citi Global Wealth provides clients with a leading investment strategies platform, which delivers traditional and alternative investments, managed account strategies and investment guidance for all clients.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
North America: Jamie Letica
LATAM: Denise Rockenbach
APAC: Harsha Jethnani

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye